ResMed (RMD) Stock Overview
Develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for RMD from our risk checks.
RMD Community Fair Values
Create NarrativeSee what 115 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ResMed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$205.02 |
| 52 Week High | US$293.81 |
| 52 Week Low | US$198.64 |
| Beta | 0.93 |
| 1 Month Change | -8.00% |
| 3 Month Change | -20.63% |
| 1 Year Change | -14.56% |
| 3 Year Change | -11.50% |
| 5 Year Change | 5.05% |
| Change since IPO | 30,414.60% |
Recent News & Updates
ResMed (RMD): The Sleep Titan Defies the Weight-Loss Disruptor
ResMed Inc. (RMD) , the global vanguard of cloud-connected sleep and respiratory care, enters the final week of April 2026 in a state of defiant operational strength.
RMD: Distribution Expansion And Margin Strength Will Support Future Upside
ResMed's analyst price target has been nudged lower by about $0.33 as analysts balance a slightly higher discount rate with firmer revenue growth, profit margin assumptions, and modest target increases from several firms alongside a more recent $5 trim from Citi. Analyst Commentary Recent Street research around ResMed reflects a mix of optimism on the company’s execution and growth profile, alongside a more cautious stance on valuation and near term expectations.Recent updates
ResMed (RMD): The Sleep Titan Defies the Weight-Loss Disruptor
ResMed Inc. (RMD) , the global vanguard of cloud-connected sleep and respiratory care, enters the final week of April 2026 in a state of defiant operational strength.RMD: Distribution Expansion And Margin Strength Will Support Future Upside
ResMed's analyst price target has been nudged lower by about $0.33 as analysts balance a slightly higher discount rate with firmer revenue growth, profit margin assumptions, and modest target increases from several firms alongside a more recent $5 trim from Citi. Analyst Commentary Recent Street research around ResMed reflects a mix of optimism on the company’s execution and growth profile, alongside a more cautious stance on valuation and near term expectations.RMD: Higher Earnings Visibility And Margins Will Support Future Upside
Analysts have lifted the consolidated ResMed price target by $15, reflecting updated views on its long term growth, margin profile and P/E assumptions in light of recent research from Citi, RBC Capital, Stifel, KeyBanc and Baird. Analyst Commentary Recent Street research points to a cluster of higher price targets for ResMed, with different teams revisiting their assumptions around growth durability, margin structure and the P/E multiple they are willing to apply.ResMed: Waiting For The Next Catalyst, Initiating With Hold Rating
Mar 16RMD: AI Sleep Personalization And New Distribution Hub Will Support Upside
ResMed's analyst price target has edged lower by about $1 to $296.87, as analysts fine tune their models around slightly different fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, while keeping an overall constructive stance. This stance is reflected in a series of recent target increases across the Street.RMD: AI Sleep Therapy Personalization Will Support Long Term Upside
ResMed's analyst price target has moved higher by several dollars to reflect a modest adjustment to discount rate assumptions, while multiple firms have raised their targets by $3 to $15. Analysts point to supportive fundamentals for the updated view.RMD: AI Sleep Therapy Personalization And Buyback Will Support Long Term Upside
Our updated ResMed narrative reflects a modest lift in the implied analyst price target to about $297.47, with analysts pointing to slightly higher assumed revenue growth, a small improvement in profit margins, and a marginally lower future P/E multiple as key drivers of the change. Analyst Commentary Recent Street research shows a cluster of upward price target revisions for ResMed, with several firms lifting their targets by between $3 and $15.RMD: AI Therapy Personalization Will Support Sustained Long Term Upside Potential
Narrative Update on ResMed Analysts have lifted their price targets on ResMed, supporting a modest fair value adjustment to about $296.40 as they factor in updated expectations for growth, profitability, and a slightly lower future P/E assumption. Analyst Commentary Recent Street research on ResMed points to a cluster of price target increases, with several bullish analysts nudging their targets higher by incremental amounts.Analyst Commentary Highlights Margin Optimism as ResMed Faces Market Headwinds and Patent Challenge
Analysts have raised their price target for ResMed to $295 from $292, citing improved profit margin expectations and better anticipated gross margin expansion. This comes despite concerns over slower market growth dynamics.We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Sep 06
Calculating The Intrinsic Value Of ResMed Inc. (NYSE:RMD)
Jul 29Shareholders Would Enjoy A Repeat Of ResMed's (NYSE:RMD) Recent Growth In Returns
Jun 23Do ResMed's (NYSE:RMD) Earnings Warrant Your Attention?
Jun 11There's Reason For Concern Over ResMed Inc.'s (NYSE:RMD) Price
May 30ResMed (NYSE:RMD) Seems To Use Debt Rather Sparingly
May 18ResMed: Cornering The Market In Sleep Solutions
Apr 24Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions
Feb 10ResMed: Snoozers Can Be Winners
Feb 01ResMed: Fully Valued With Medium-Term Challenges (Rating Downgrade)
Jan 24ResMed: Solid Execution, Pricey Valuation
Nov 25Why ResMed's Rally Is Just Getting Started
Sep 18Shareholder Returns
| RMD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -6.7% | -4.3% | 0.8% |
| 1Y | -14.6% | -18.7% | 27.7% |
Return vs Industry: RMD exceeded the US Medical Equipment industry which returned -18.7% over the past year.
Return vs Market: RMD underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| RMD volatility | |
|---|---|
| RMD Average Weekly Movement | 4.0% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: RMD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RMD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 10,600 | Mick Farrell | www.resmed.com |
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution.
ResMed Inc. Fundamentals Summary
| RMD fundamental statistics | |
|---|---|
| Market cap | US$31.01b |
| Earnings (TTM) | US$1.49b |
| Revenue (TTM) | US$5.40b |
Is RMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.24 |
| Gross Margin | 61.47% |
| Net Profit Margin | 27.53% |
| Debt/Equity Ratio | 10.5% |
How did RMD perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/01 11:11 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ResMed Inc. is covered by 46 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| Michael Polark | Baird |
| Matthew Taylor | Barclays |